Mice completely cured by IL-2/JES6 alone or ICIs plus IL-2/JES6 were highly resistant to CT26 tumor rechallenge (online supplemental figure 8B and C), demonstrating that treatment led to robust, durable antitumor immunity. The gene discussed is IL2; the disease is neoplasm.